The use of botulinum toxin type A in the treatment of HTLV-1-associated overactive bladder refractory to conventional therapy

• Autor(a) principal: Carneiro Neto,José Abraão
• Data de Publicação: 2014
• Outros Autores: Bittencourt,Valéria Gusmão, de Oliveira,Cassius, Andrade,Rosana, de Carvalho,Edgar Marcelino
• Tipo de documento: Relatório
• Idioma: eng
• Título da fonte: Revista da Sociedade Brasileira de Medicina Tropical
• Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0037-86822014000400528
• topic: HTLV-1; Overactive bladder; Botox

Urinary symptoms occur in 19% of human T-cell lymphotropic virus type 1 (HTLV-1)-infected patients who do not fulfill criteria for HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) and in almost 100% of HAM/TSP patients. Few studies have evaluated therapies for overactive bladder (OAB) caused by HTLV-1 infection. This case report describes the effect of onabotulinum toxin A on the urinary manifestations of three patients with HAM/TSP and OAB symptoms. The patients were intravesically administered 200 units of Botox®. Their incontinence episodes improved, and their OAB symptoms scores (OABSS) reduced significantly. These data indicate that Botox® should be a treatment option for OAB associated with HTLV-1 infection.